Latest News and Press Releases

SYDNEY, Australia, May 04, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (Immutep or the Company) today announced that it will present posters during the 2018 American Society for...

SYDNEY, Australia, April 12, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep” or the “Company”) advises that its Share Purchase Plan (“SPP”) closed as planned on 6 April...

First two patients of the additional cohort of the Phase I, TACTI-mel trial have commenced treatment; data to be reported mid-2018AIPAC trial: 33 out of a planned 34 clinical sites now active with...

SYDNEY, Australia, March 22, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep” or the “Company”) is pleased to announce the presentation of updated data from its TACTI-mel...

SYDNEY, Australia, March 21, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep” or the “Company”) has announced the initiation of patient dosing in the new cohort of the...

A$6.85m raised through share institutional placement to drive immuno-oncology development programsPlacement of new ordinary shares to leading Australian healthcare institutional investors Platinum...

SYDNEY, Australia, March 11, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep” or the “Company”) has announced that it has entered into a clinical trial collaboration and...

SYDNEY, Australia, March 05, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep”, the “Company”) announces the grant of patent no. 9,908,936 entitled “Antibody molecules to...

SYDNEY, Australia, March 04, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$686,704 cash rebate from...

SYDNEY, Australia, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep” or the “Company”), announced today that the Database Safety Monitoring Board (“DSMB”)...